Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF (ARCA: AZTD)

Latest news for Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF (ARCA:AZTD)

Technology

Consumer Defensive

Industrials

Utilities

Healthcare

Basic Materials

Consumer Cyclical

Financial Services

Communication Services

Other

The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The Index is based on a proprietary methodology created by Aztlan Equity Management, LLC (Aztlan) that follows a non-discretionary, rules-based methodology to determine the universe of potential Index components. The Index is owned, calculated, administered, and published by Solactive AG (Solactive).

Solvay Sa

H2o Retailing Corp

Maplebear Inc

Lazard Inc Common Stock Usd.01

Griffon Corp.

Kyndryl Hldgs Inc

Taiheiyo Cement Corp

Darktrace Plc

Aztlan Global Stock Selection DM SMID ETF

Instacart

Equities

News

Contracts

Markets

Movers

General

Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF

AZTD

CART

MVPA

Maplebear (Instacart) partners with Sally Beauty for nationwide same-day delivery, enhancing access to beauty products amid contrasting stock performances.

Instacart Inks Nationwide Pact With Sally Beauty - What&#39;s Going On?

Qr,Code,Payment,,Customer,Using,Smartphone,For,Paying,At,Shop

Media

FOUR

Fiserv and Amadeus competing for $7B acquisition of Shift4 Payments. Final bids expected soon, but outcome uncertain. Shift4 reports strong growth and interest from potential buyers in financial services sector.

Shift4 Payments in Acquisition Spotlight, Fiserv and Amadeus Poised for Billion-Dollar Bidding War

<p>Throughout the last three months, 10 analysts have evaluated Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.2, a high estimate of $75.00, and a low estimate of $45.00. Surpassing the previous average price target of $60.00, the current average has increased by 3.67%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024140_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Dave among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Announces</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeff Cantwell</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$54.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dave. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dave compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Dave's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dave's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DAVE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dave analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Dave</h2>
<p>Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.</p>
<h3>Dave: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Dave displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>24.95%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Dave's net margin excels beyond industry benchmarks, reaching <strong>46.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Dave's ROE excels beyond industry benchmarks, reaching <strong>31.95%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dave's ROA excels beyond industry benchmarks, reaching <strong>12.93%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.6</strong>, Dave adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

DAVE

A Glimpse Into The Expert Outlook On Dave Through 10 Analysts

<p>In the latest quarter, 4 analysts provided ratings for Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Dover, presenting an average target of $205.0, a high estimate of $219.00, and a low estimate of $193.00. This upward trend is apparent, with the current average reflecting a 3.4% increase from the previous average price target of $198.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024126_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Dover by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$193.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dover. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dover compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dover's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dover's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dover analyst ratings.</strong></a></p>
<h2>Get to Know Dover Better</h2>
<p>Dover is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.</p>
<h3>Key Indicators: Dover's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Dover displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.72%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Dover's net margin is impressive, surpassing industry averages. With a net margin of <strong>30.19%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dover's ROE excels beyond industry benchmarks, reaching <strong>12.32%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.42%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Dover's debt-to-equity ratio surpasses industry norms, standing at <strong>0.77</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Dover Stock

<p><strong>LuxUrban Hotels Inc. ("LuxUrban" or the "Company")</strong> <strong>(NASDAQ:</strong><a href="https://www.benzinga.com/stock/LUXH#NASDAQ"><strong>LUXH</strong></a><strong>)</strong>, which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, today announced the launch of a proposed follow-on public offering of shares of its common stock. The Company also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock sold in this offering.</p>


Offerings

LUXH

LuxUrban Hotels Launches Proposed Public Offering; No Size Or Amount Disclosed

VTVT

Trading Halt: Halted at 4:01:47 p.m. ET - Trading Halt: Halt News Pending

<p>During the last three months, 15 analysts shared their evaluations of Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Universal Health Servs, revealing an average target of $197.27, a high estimate of $256.00, and a low estimate of $162.00. Marking an increase of 9.9%, the current average surpasses the previous average price target of $179.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024102_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Universal Health Servs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$220.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$183.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Health Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Universal Health Servs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Universal Health Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Universal Health Servs analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Universal Health Servs</h2>
<p>Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.</p>
<h3>Understanding the Numbers: Universal Health Servs's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Universal Health Servs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.85%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Universal Health Servs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.81%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Universal Health Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.22%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Universal Health Servs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.87%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Universal Health Servs's debt-to-equity ratio is below the industry average at <strong>0.85</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 15 Analyst Recommendations For Universal Health Servs

<p>Kentucky&#8217;s expedited <a href="https://www.benzinga.com/markets/cannabis/24/06/39537843/applications-open-kentucky-set-to-roll-out-medical-cannabis-in-2025">licensing process for medical cannabis</a> has seen significant interest, but the number of formal applications remains low, <a href="https://www.cannabisbusinesstimes.com/news/kentucky-medical-marijuana-legalization-licenses-sales-regulations-timeline-when-start-where-buy/">reported</a> by Cannabis Business Times. The state&#8217;s licensing portal, opened on July 1, has registered 489 accounts, yet only 17 applications have been submitted for the 74 available licenses as of July 19. The Kentucky Cabinet for Health and Family Services (CHFS), which oversees the state&#8217;s cannabis program, is processing these applications.</p>
<h3 class="wp-block-heading">Slow Start For High Demand</h3>
<p>Despite the initial rush to register on the licensing portal, the number of formal applications has been underwhelming. Of the 17 submitted applications, 11 are for dispensary licenses, two for processor licenses, and four for cultivator licenses. The state allows applicants to submit multiple applications within a license type but prohibits vertically integrated operations from the program onset.</p>
<h3 class="wp-block-heading">Regulatory and Economic Challenges</h3>
<p>Applicants must demonstrate they have sufficient capital, ranging from $50,000 for Tier 1 cultivators to $500,000 for Tier 3 cultivators. This financial burden, along with nonrefundable application fees, may be contributing to the slow application rate. Some registrants could still be in the process of raising the necessary capital.</p>
<p>Governor <strong>Andy Beshear</strong> has been a vocal advocate for cannabis reform in <a href="https://www.benzinga.com/topic/kentucky#more-news">Kentucky</a>, having <a href="https://www.benzinga.com/markets/cannabis/22/11/29748349/another-state-legalizes-mmj-possession-but-heres-what-kentucky-gov-beshears-exec-order-says">signed the medical cannabis legalization bill</a> in March 2023 and House Bill 829 in April 2024, which expedited the licensing timeline by six months. "This administration has been working hard to expedite the timeline for making medical cannabis available to Kentuckians with serious medical conditions," Beshear said in a recent press release.</p>
<h3 class="wp-block-heading">Criticism From Advocacy Groups</h3>
<p>Despite Beshear&#8217;s efforts, cannabis advocacy group NORML has criticized certain provisions in H.B. 829. These include criminal background checks for patients with previous felony convictions and mandatory evaluations of patients&#8217; medical histories before issuing medical cannabis recommendations. <strong>Lauren Bratcher</strong>, deputy director of Kentucky NORML, argued that these restrictive measures could hinder patient access to medical cannabis.</p>
<h3 class="wp-block-heading">Future Prospects And Industry Sentiment</h3>
<p>Kentuckians can begin applying for medical cannabis cards on January 1, 2025, though the timeline for dispensary sales remains unspecified. The state's regulators are partnering with medical boards to ensure that authorized physicians and nurses are available to issue medical cannabis certifications.</p>
<p>CHFS Secretary <strong>Eric Friedlander</strong> emphasized the administration&#8217;s commitment to safe and affordable access to medical cannabis. To support a fair and transparent licensing process, the state has provided resources, including YouTube webinars and a business licensing application guide, to assist applicants.</p>
<p>With over five weeks remaining in the application period, there is still time for interested parties to finalize their applications. The current interest suggests a promising future for Kentucky's medical cannabis industry though the slow start highlights the financial and regulatory hurdles that prospective operators face.</p>
<p><em>Cover image made with AI</em></p>


Cannabis

Regulations

Retail Sales

Kentucky's Medical Marijuana Licensing Process Off To A Slow Start Despite Lots Of Interest, Here's Why

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Align Tech</strong>.</p>
<p>Looking at options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $229,860 and 3, calls, for a total amount of $341,228.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $280.0 for Align Tech over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Align Tech options trades today is 127.12 with a total volume of 540.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Align Tech's big money trades within a strike price range of $160.0 to $280.0 over the last 30 days.</p>
<h3>Align Tech Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024086_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.1</td>
<td>$19.3</td>
<td>$20.5</td>
<td>$240.00</td>
<td>$195.0K</td>
<td style="text-align: right;">177</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.5</td>
<td>$9.0</td>
<td>$9.75</td>
<td>$280.00</td>
<td>$117.0K</td>
<td style="text-align: right;">239</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$40.1</td>
<td>$37.2</td>
<td>$40.2</td>
<td>$260.00</td>
<td>$80.4K</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$5.2</td>
<td>$4.3</td>
<td>$5.2</td>
<td>$230.00</td>
<td>$51.4K</td>
<td style="text-align: right;">130</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$23.2</td>
<td>$22.8</td>
<td>$22.8</td>
<td>$220.00</td>
<td>$38.7K</td>
<td style="text-align: right;">74</td>
<td style="text-align: right;">18</td>
</tr>
</tbody>
</table>
</p>
<h3>About Align Tech</h3>
<p>Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.</p>
<p>After a thorough review of the options trading surrounding Align Tech, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Align Tech</h3>
<ul>
<li>Trading volume stands at 950,728, with ALGN's price down by -2.36%, positioned at $220.72.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>What The Experts Say On Align Tech</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $326.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Align Tech with a target price of $310. </li>
<li>Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Align Tech, targeting a price of $325. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Align Tech with a target price of $330. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Align Tech, targeting a price of $315. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Align Tech with a target price of $350. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

ALGN

Align Tech Unusual Options Activity

<p>HC Wainwright &amp; Co.  analyst Edward White   reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $7 price target.</p>


Price Target

Reiteration

PBYI

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Viking Therapeutics</strong>.</p>
<p>Looking at options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) we detected 39 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $81,740 and 36, calls, for a total amount of $1,562,212.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $100.0 for Viking Therapeutics over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Viking Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Viking Therapeutics's significant trades, within a strike price range of $20.0 to $100.0, over the past month.</p>
<h3>Viking Therapeutics Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024081_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.0</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$100.00</td>
<td>$124.5K</td>
<td>2.4K</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$5.5</td>
<td>$4.4</td>
<td>$5.5</td>
<td>$80.00</td>
<td>$82.2K</td>
<td>1.7K</td>
<td style="text-align: right;">252</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$27.0</td>
<td>$24.5</td>
<td>$27.0</td>
<td>$40.00</td>
<td>$81.0K</td>
<td>34</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$100.00</td>
<td>$70.0K</td>
<td>2.6K</td>
<td style="text-align: right;">375</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$6.3</td>
<td>$6.0</td>
<td>$6.3</td>
<td>$65.00</td>
<td>$63.0K</td>
<td>1.5K</td>
<td style="text-align: right;">287</td>
</tr>
</tbody>
</table>
</p>
<h3>About Viking Therapeutics</h3>
<p>Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.</p>
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a volume of 8,312,421, the price of VKTX is up 2.5% at $66.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 89 days.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $104.33333333333333.</p>
<ul>
<li>In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $90. </li>
<li>Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Viking Therapeutics, targeting a price of $118. </li>
<li>Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Overweight with a new price target of $105.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VKTX

Viking Therapeutics's Options: A Look at What the Big Money is Thinking

<p>In the latest quarter, 4 analysts provided ratings for Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Alignment Healthcare, presenting an average target of $9.25, a high estimate of $12.00, and a low estimate of $7.00. This current average reflects an increase of 32.14% from the previous average price target of $7.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024081_0_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Alignment Healthcare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alignment Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alignment Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Alignment Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Alignment Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alignment Healthcare analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Alignment Healthcare: A Closer Look</h2>
<p>Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.</p>
<h3>Alignment Healthcare: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Alignment Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>43.14%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Alignment Healthcare's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-7.4%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Alignment Healthcare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-32.32%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Alignment Healthcare's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-7.59%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Alignment Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.3</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALHC

Critical Insights From Alignment Healthcare Analyst Ratings: What You Need To Know

<p>Deep-pocketed investors have adopted a bullish approach towards Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UPST usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Upstart Hldgs. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 43% bearish. Among these notable options, 3 are puts, totaling $119,326, and 13 are calls, amounting to $606,162.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $100.0 for Upstart Hldgs over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Upstart Hldgs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Upstart Hldgs's whale trades within a strike price range from $15.0 to $100.0 in the last 30 days. </p>
<h3>Upstart Hldgs Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024076_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$0.48</td>
<td>$0.42</td>
<td>$0.46</td>
<td>$29.00</td>
<td>$127.8K</td>
<td>2.3K</td>
<td style="text-align: right;">925</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.1</td>
<td>$9.9</td>
<td>$11.0</td>
<td>$25.00</td>
<td>$88.0K</td>
<td>541</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.25</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$70.00</td>
<td>$57.5K</td>
<td>1.2K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/23/24</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$27.00</td>
<td>$55.2K</td>
<td>55</td>
<td style="text-align: right;">223</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/09/24</td>
<td>$1.85</td>
<td>$1.73</td>
<td>$1.73</td>
<td>$30.00</td>
<td>$43.2K</td>
<td>1.0K</td>
<td style="text-align: right;">312</td>
</tr>
</tbody>
</table>
</p>
<h3>About Upstart Hldgs</h3>
<p>Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.</p>
<h3>Current Position of Upstart Hldgs</h3>
<ul>
<li>With a volume of 3,428,753, the price of UPST is up 4.89% at $27.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Upstart Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


UPST

Upstart Hldgs's Options: A Look at What the Big Money is Thinking

<p>Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 3.12% on an annualized basis producing an average annual return of 15.05%. Currently, Analog Devices has a market capitalization of $112.13 billion. </p>
<p><strong>Buying $1000 In ADI:</strong> If an investor had bought $1000 of ADI stock 15 years ago, it would be worth <strong>$8,256.12</strong> today based on a price of $225.97 for ADI at the time of writing.</p>
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024073_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much $1000 Invested In Analog Devices 15 Years Ago Would Be Worth Today

<p>Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.12%. Currently, Ball has a market capitalization of $19.26 billion. </p>
<p><strong>Buying $1000 In BALL:</strong> If an investor had bought $1000 of BALL stock 20 years ago, it would be worth <strong>$6,935.82</strong> today based on a price of $62.05 for BALL at the time of writing.</p>
<h3>Ball's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024068_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BALL

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,900 Today

<p>Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor&#39;s dream. However, when you&#39;re an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.</p>
<p>Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.</p>
<p><strong>Equinix in Focus</strong></p>
<p>Headquartered in Redwood City, <strong>Equinix</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eqix#NASDAQ">EQIX</a>) is a Finance stock that has seen a price change of -4.48% so far this year. Currently paying a dividend of $4.26 per share, the company has a dividend yield of 2.21%. In comparison, the REIT and Equity Trust - Retail industry&#39;s yield is 4.23%, while the S&amp;P 500&#39;s yield is 1.58%.</p>
<p>Looking at dividend growth, the company&#39;s current annualized dividend of $17.04 is up 17.6% from last year. Over the last 5 years, Equinix has increased its dividend 5 times on a year-over-year basis for an average annual increase of 11.52%. Future dividend growth will depend on earnings growth as well as payout ratio, which is the proportion of a company&#39;s annual earnings per share that it pays out as a dividend. Right now, Equinix&#39;s payout ratio is 53%, which means it paid out 53% of its trailing 12-month EPS as dividend.</p>
<p>Earnings growth looks solid for EQIX for this fiscal year. The Zacks Consensus Estimate for 2024 is $34.98 per share, with earnings expected to increase 8.94% from the year ago period.</p>
<p><strong>Bottom Line</strong></p>
<p>Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout.</p>
<p>Big, established firms that have more secure profits are often seen as the best dividend options, but it&#39;s fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, EQIX presents a compelling investment opportunity; it&#39;s not only an attractive dividend play, but the stock also boasts a strong Zacks Rank of #2 (Buy).</p>
<p><a href="https://www.zacks.com/stock/news/2310200/equinix-eqix-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2310200">To read this article on Zacks.com click here.</a></p>


Earnings

Dividends

EQIX

Equinix Could Be a Great Choice

<p>In the preceding three months, 10 analysts have released ratings for LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.4, with a high estimate of $67.00 and a low estimate of $50.00. Marking an increase of 19.33%, the current average surpasses the previous average price target of $48.10. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024055_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive LendingTree. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LendingTree. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of LendingTree compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of LendingTree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of LendingTree's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TREE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on LendingTree analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into LendingTree's Background</h2>
<p>LendingTree Inc is a United States-based company that is principally engaged in operating an online loan marketplace. The company provides online tools and resources that can help consumers find loans or other credit-based offerings They need, including mortgage loans, reverse mortgage, home equity, personal loans, auto loans, credit cards, student loans, small business loans, and other related offerings. The company offers consumers direct access to a broad range of lenders. They have three reportable segments which are Home, Consumer, and Insurance. The company generates match fees by matching consumers with lenders, and closing fees from lenders on loans when a transaction is closed. The company operates business solely in the United States.</p>
<h3>Key Indicators: LendingTree's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> LendingTree's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately <strong>-16.33%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> LendingTree's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>0.61%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LendingTree's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> LendingTree's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> LendingTree's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>5.52</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TREE

What 10 Analyst Ratings Have To Say About LendingTree

<p>In the preceding three months, 4 analysts have released ratings for Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $31.5, a high estimate of $34.00, and a low estimate of $29.00. This current average reflects an increase of 12.5% from the previous average price target of $28.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024031_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Five Star. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Five Star. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Five Star compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Five Star's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Five Star's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FSBC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Five Star analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Five Star</h2>
<p>Five Star Bancorp is a California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts.</p>
<h3>Five Star: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Five Star faced challenges, resulting in a decline of approximately <strong>-6.56%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Five Star's net margin is impressive, surpassing industry averages. With a net margin of <strong>37.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Five Star's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.68%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Five Star's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.3%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Five Star's debt-to-equity ratio is below the industry average at <strong>0.69</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FSBC

Analyst Scoreboard: 4 Ratings For Five Star

Petrobras Director Of E&P Says Petrobras Made Non-Binding Offer For A Share Of Galp's Mopane Oil Field In Namibia, Would Make Petrobras Operator Of Mopane Field, With At Least 10B Barrels Of Oil Equivalent; Looking For Oil Reserves Abroad Due To Environmental Licensing Issues For New Areas In Brazil

<p>Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor&#39;s dream. But when you&#39;re an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.</p>
<p>Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.</p>
<p><strong>Principal Financial in Focus</strong></p>
<p>Based in Des Moines, <strong>Principal Financial</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfg#NYSE">PFG</a>) is in the Finance sector, and so far this year, shares have seen a price change of 7.31%. Currently paying a dividend of $0.71 per share, the company has a dividend yield of 3.36%. In comparison, the Financial - Investment Management industry&#39;s yield is 2.73%, while the S&amp;P 500&#39;s yield is 1.58%.</p>
<p>In terms of dividend growth, the company&#39;s current annualized dividend of $2.84 is up 9.2% from last year. Over the last 5 years, Principal Financial has increased its dividend 4 times on a year-over-year basis for an average annual increase of 5.32%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company&#39;s annual earnings per share that it pays out as a dividend. Principal Financial&#39;s current payout ratio is 41%, meaning it paid out 41% of its trailing 12-month EPS as dividend.</p>
<p>PFG is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2024 is $7.43 per share, with earnings expected to increase 13.44% from the year ago period.</p>
<p><strong>Bottom Line</strong></p>
<p>Investors like dividends for a variety of different reasons, from tax advantages and decreasing overall portfolio risk to considerably improving stock investing profits. However, not all companies offer a quarterly payout.</p>
<p>For instance, it&#39;s a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It&#39;s more common to see larger companies with more established profits give out dividends. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, PFG is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold).</p>
<p><a href="https://www.zacks.com/stock/news/2310204/principal-financial-pfg-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2310204">To read this article on Zacks.com click here.</a></p>


Principal Financial Could Be a Great Choice

<p>Needham  analyst Gil Blum   reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and maintains $6 price target.</p>


GERN

Needham Reiterates Buy on Geron, Maintains $6 Price Target

<p><strong>IPG Photonics</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipgp#NASDAQ">IPGP</a>) is slated to release its second-quarter 2024 results on Jul 30.</p>
<p>For the second quarter, the company anticipates sales in the range of $240-$270 million. Earnings per share are projected between 30 cents and 60 cents.</p>
<p>The Zacks Consensus Estimate for earnings is pegged at 48 cents per share, unchanged over the past 30 days. The company reported earnings of $1.31 per share in the year-ago quarter.</p>
<p>The consensus mark for revenues stands at $255.4 million, suggesting a decrease of 24.88% from the year-ago quarter.</p>
<div class="chart_embed">
<h3>IPG Photonics Corporation Price and EPS Surprise</h3>
<p><img alt="IPG Photonics Corporation Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/91/1722005506.png" style="height:303px; width:620px" title="" /></p>
<p><span style="font-size:13px">IPG Photonics Corporation price-eps-surprise</span><span style="font-size:13px"> | IPG Photonics Corporation Quote</span></p>
<p>IPG Photonics&#39; earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing the same once, the average surprise being 5.63%.</p>
<p>Let&#39;s see how things have shaped up for this announcement.</p>
</div>
<h3>Factors to Note</h3>
<p>IPG Photonics is expected to have suffered from lower materials processing sales, primarily due to weakness in cutting and marking applications. The Zacks Consensus Estimate for Materials Processing revenues for the second quarter is pegged at $227 million, indicating a decline of 27.7% year over year.</p>
<p>Continued economic uncertainty with low PMI numbers in Europe, North America and Japan is likely to have negatively impacted industrial demand and capital investments in the quarter under review.</p>
<p>However, IPGP is expected to have benefited from strong demand for the handheld welder, LightWELD. The company is focusing on key growth markets and applications, including welding, cleaning, heating and medical applications. These areas are expected to have benefited top-line growth by diversifying revenues away from more competitive applications, such as cutting and marking.</p>
<p>IPG is also starting to ship handheld welding devices to Miller Electric, which is expected to have boosted welder sales in the second quarter and have a more measurable impact in the second half of the year. Additionally, the order pipeline and customer interest for handheld welders remain strong.</p>
<p>Revenues in 3D printing applications also increased as the industry continues to use high-quality lasers for metal powder melting to create parts. IPG&#39;s strong position in this market is expected to have bolstered revenue growth in the to-be-reported quarter.</p>
<p>Revenues from IPG Photonics&#39; emerging growth products accounted for 45% of total sales in the first quarter of 2024. These products, which improve the speed and quality of manufacturing processes while reducing energy consumption and environmental impacts, are expected to have contributed significantly to overall revenues.</p>
<h3>What Our Model Says</h3>
<p>Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that&#39;s not the case here.</p>
<p>IPG Photonics has an Earnings ESP of 0.00% and a Zacks Rank #2 at present.</p>
<h3>Stocks to Consider</h3>
<p>Here are some companies worth considering, as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:</p>
<p><strong>Arista Networks</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anet#NYSE">ANET</a>) has an Earnings ESP of +0.95% and sports a Zacks Rank #1 at present.</p>
<p>Arista Networks&#39; shares have gained 33.4% year to date. ANET is set to report its second-quarter 2024 results on Jul 30.</p>
<p><strong>Apple</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) has an Earnings ESP of +3.23% and a Zacks Rank of 2 at present.</p>
<p>Apple&#39;s shares have gained 13% year to date. AAPL is set to report its third-quarter fiscal 2024 results on Aug 1.</p>
<p><strong>Cognizant Technology Solutions</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctsh#NASDAQ">CTSH</a>) has an Earnings ESP of +0.09% and a Zacks Rank #2 at present.</p>
<p>Cognizant Technology Solutions&#39; shares have lost 3.1% year to date. CTSH is set to report second-quarter 2024 results on Jul 31.</p>
<p><a href="https://www.zacks.com/stock/news/2310274/ipg-photonics-ipgp-to-post-q2-earnings-what-s-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2310274">To read this article on Zacks.com click here.</a></p>


Tech

AAPL

ANET

CTSH

IPGP

IPG Photonics to Post Q2 Earnings: What's in the Cards?

<p>On Tuesday, <strong>Maplebear Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), popularly known as Instacart, inked a pact with <strong>Sally Beauty Holdings, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>).</p>



<p>The companies announced a nationwide partnership to offer same-day delivery in as fast as an hour from more than <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/n39378492/sally-beauty-and-instacart-announce-nationwide-partnership-to-offer-same-day-delivery" rel="noreferrer noopener">2,200 Sally Beauty store locations across the country.</a></p>



<p>&#8220;This partnership not only enhances Sally Beauty&#8217;s e-commerce capabilities but also addresses the growing demand for quick delivery of everyday beauty products, ensuring customers can receive their essentials when they need them,&#8221; said&nbsp;Blake Wallace, Senior Director of Retail Partnerships at Instacart.</p>



<p>According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CART stock has gained 34% in the last six months. Investors can gain exposure to the stock via&nbsp;<strong>Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTD#NYSE">AZTD</a>)</p>



<p>and&nbsp;<strong>Advisor Managed Portfolios Miller Value Partners Appreciation ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MVPA#NYSE">MVPA</a>).</p>



<p>After a successful initial partnership earlier this year, Sally Beauty and Instacart have expanded their collaboration nationwide.</p>



<p>This combines Instacart&#8217;s delivery network with Sally Beauty&#8217;s wide array of beauty products, enhancing convenience for consumers.</p>



<p>&#8220;We remain focused on putting our customers first by offering the latest technology and shopping options to ensure they have greater access to all their beauty essentials,&#8221; said&nbsp;Natalie Lockhart, Group Vice President of Strategy, Customer Insights &amp; Digital Experience at Sally Beauty.</p>



<p>SBH stock has lost over 19% in the last six months.</p>



<p><strong>Price Action: </strong>CART shares are trading higher by 1.17% to $33.63 at last check Tuesday, while SBH shares are trading lower by 1.54%.</p>



<p><em>Image via Shutterstock</em></p>

Instacart Inks Nationwide Pact With Sally Beauty - What's Going On?

<p><strong>Fiserv, Inc&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) and&nbsp;<strong>Amadeus IT Group</strong>&nbsp;are in the race to acquire&nbsp;<strong>Shift4 Payments Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), a payment processing firm valued at nearly $7 billion.&nbsp;</p>



<p>These two leading contenders are preparing their final bids in the upcoming weeks, although the outcome of these negotiations remains uncertain, Reuters reports.&nbsp;</p>



<p>This week, Shift4 Payments reported fourth-quarter fiscal 2023 gross revenue growth of 31% year-on-year to $705.4 million, lagging the consensus of $$757.8 million. Adjusted EPS of 76 cents missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/02/37340983/shift4-payments-misses-q4-expectations-outlines-bold-growth-targets-for-2024" rel="noreferrer noopener">consensus of 82 cents</a>.</p>



<p><strong><em>Also Read:</em></strong><em>&nbsp;</em><a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37379636/shift4-payments-analysts-highlight-growth-opportunities-despite-q4-challenges" rel="noreferrer noopener"><em>Shift4 Payments: Analysts Highlight Growth Opportunities Despite Q4 Challenges</em></a></p>



<p>Shift4 Payments processes over $200 billion in transactions annually for more than 200,000 clients.&nbsp;</p>



<p>The interest in Shift4 Payments indicates the broader trend in the financial services sector, where companies have sought to expand their capabilities through strategic acquisitions.&nbsp;</p>



<p>Fiserv, a major player in providing transaction processing services with a market capitalization of about $89 billion, previously acquired First Data for $22 billion in 2019.&nbsp;</p>



<p>On the other hand, Amadeus, a Spain-based technology provider for the travel industry valued at approximately 27 billion euros, looks to enhance its travel booking solutions with a potential Shift4 acquisition.</p>



<p>The pursuit of Shift4 Payments came when the payment processing industry faced challenges maintaining growth due to increased competition and economic pressures.&nbsp;</p>



<p>However, Shift4&#8217;s recent earnings report and optimistic outlook for 2024 suggest resilience and potential for further expansion. CEO Jared Isaacman has openly discussed the company&#8217;s consideration of strategic alternatives.</p>



<p><strong>Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTD#NYSE">AZTD</a>), which has close to 4% exposure to Shift4 Payments, gained 2.4% in the last six months.</p>



<p><strong>Price Action:</strong>&nbsp;FOUR shares traded higher by 2.44% at $88.00 premarket on the last check Thursday.</p>



<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>



<p><em>Photo by Nattakorn_Maneerat via Shutterstock</em></p>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF

News

Latest news for Tidal ETF Trust Aztlan Global Stock Selection DM SMID ETF (ARCA:AZTD)

Tuesday, June 18, 2024

Thursday, February 29, 2024